Creating
the Super Lifeform

We firmly believe that health is not only the cornerstone of life but also the eternal
theme of humanity's pursuit of youthfulness, vitality, and beauty.

Learn More

GLP-1 Receptor Agonist
High-quality Biosimilars

A Breakthrough Solution for Type 2 Diabetes and Weight Management

Learn More

Cellular
Regenerative
Medicine

Non-Tumorigenic Clinical-Grade UC-MSCs and Exosome
Combined Therapy

Learn More

ABOUT US

Our Global Biomedical Group

XAMANO Pharmaceutical Group is driven by the mission to promote the values of super lifeform – characterized by greater health, youthfulness, and beauty – for all humankind.

We are dedicated to deeply exploring the infinite possibilities of life evolution through the breakthrough application of cutting-edge biotechnologies such as gene editing, stem cell technology, and metabolic medicine, supported by our global R&D network.

The Group has established five synergistic centers worldwide, located in China, Brazil, Bulgaria, Australia, and Canada. Through our "Localized R&D + Global Resource Synergy" framework, we have built a fully-integrated innovation ecosystem encompassing fundamental research, clinical validation (multi-center real-world studies), and commercialization.

DEVELOPMENT TIMELINE

Since 2020

XAMANO was established in Brazil, focusing on clinical research, GMP certification, market registration (NDA/BLA), CSO, and other services for vaccines, innovative biologics, and regenerative medicine.

In 2021

The company strategically expanded into the GLP-1 field, establishing the XAMANO Biomedicine R&D Center in Australia.

In 2022

The company invested and participated in the research and development of Semaglutide. The company has completed the Phase 1 clinical trial in China.

In 2023

The GLP-1 pharmaceutical production facility in China officially commenced operations.

In 2024

The company initiated clinical trials for cell therapies, including CAR-T therapy, in Latin America and Eastern Europe. The same year, the company made significant advancements in targeted cell therapy technologies.

In 2025

The company completed Phase III clinical trials for XAMANO^®Semaglutide and initiated commercial launches in markets including Southeast Asia, Central Asia,Latin America, and the Middle East.

CORPORATE HONORS

The Chairman of the Group Company had a cordial meeting with Senator Veneziano Vital do Rêgo, who also serves as the Vice President of Brazil’s Federal Senate.

Mr.Antônio Barra Torres, President-Director of ANVISA (Brazilian Health Regulatory Agency), held a roundtable meeting with representatives of XAMANO Company.